Boston Scientific Corporation (NYSE:BSX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Boston Scientific has a consensus analyst rating of “Moderate Buy” from 30 brokerages, with 23 buy ratings and an average 1-year price target of $85.08.
• Company insiders have been buying shares recently, including two directors who purchased stock in May; insider buying over the last three months totaled 9,800 shares worth about $554,012.
• The company reported better-than-expected quarterly results, with EPS of $0.80 and revenue of $5.20 billion, and it also authorized a $5 billion share repurchase program.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirty brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $85.08.

BSX has been the subject of a number of research analyst reports. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Piper Sandler reiterated an "overweight" rating and issued a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. BTIG Research restated a "buy" rating and set a $65.00 target price on shares of Boston Scientific in a research report on Tuesday, June 16th. Leerink Partners lowered their price target on Boston Scientific from $87.00 to $74.00 and set an "outperform" rating for the company in a report on Thursday, May 28th. Finally, Zacks Research cut Boston Scientific from a "hold" rating to a "strong sell" rating in a research report on Friday, June 5th.

Insider Buying and Selling

In related news, Director Edward J. Ludwig bought 3,580 shares of the company's stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company's stock, valued at approximately $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the company. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth about $26,000. Colonial Trust Co SC raised its holdings in shares of Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after buying an additional 231 shares during the last quarter. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. Finally, Bangor Savings Bank boosted its position in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 142 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $45.30 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm's 50 day moving average is $54.71 and its two-hundred day moving average is $72.83. Boston Scientific has a 52 week low of $44.44 and a 52 week high of $109.50. The firm has a market capitalization of $67.33 billion, a P/E ratio of 18.95, a P/E/G ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific's quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.